KBC Group NV Has $1.04 Million Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

KBC Group NV lowered its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 69.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 98,674 shares of the company's stock after selling 224,828 shares during the quarter. KBC Group NV's holdings in Elanco Animal Health were worth $1,036,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. CoreCap Advisors LLC bought a new stake in Elanco Animal Health during the 4th quarter worth about $29,000. Parallel Advisors LLC boosted its stake in shares of Elanco Animal Health by 92.2% in the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after purchasing an additional 1,852 shares during the last quarter. NBC Securities Inc. bought a new position in shares of Elanco Animal Health in the 1st quarter valued at about $40,000. Jones Financial Companies Lllp boosted its stake in shares of Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after purchasing an additional 2,059 shares during the last quarter. Finally, Versant Capital Management Inc boosted its stake in shares of Elanco Animal Health by 65.9% in the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after purchasing an additional 1,740 shares during the last quarter. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Trading Up 1.7%

Shares of NYSE:ELAN traded up $0.25 during mid-day trading on Tuesday, reaching $14.72. The stock had a trading volume of 2,930,061 shares, compared to its average volume of 5,072,437. The firm has a market cap of $7.31 billion, a PE ratio of 19.89, a price-to-earnings-growth ratio of 2.86 and a beta of 1.67. The firm has a 50 day simple moving average of $13.03 and a two-hundred day simple moving average of $11.61. The company has a current ratio of 2.71, a quick ratio of 1.46 and a debt-to-equity ratio of 0.68. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $15.78.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.31 by $0.06. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. The business's quarterly revenue was down 1.0% on a year-over-year basis. During the same period last year, the company posted $0.34 EPS. On average, research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ELAN. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. Stifel Nicolaus raised their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. Finally, Wall Street Zen raised shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $15.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.